Sunil Healthcare Reports Mixed Financial Results for Q2 2024, Operating Profit Improves

Sunil Healthcare, a microcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financial report, Sunil Healthcare has seen a negative performance in the second quarter of the fiscal year 2024-2025. However, there has been a slight improvement in the company's score, which has gone from -7 to -6 in the last three months.

One of the positive aspects of Sunil Healthcare's financials is its operating profit to interest ratio, which is the highest it has been in the last five quarters at 1.55 times. This indicates that the company's ability to manage its interest payments is improving.

On the other hand, there are some areas where Sunil Healthcare needs to work on based on its September 2024 financials. The company's operating cash flow has been consistently falling over the last three years, with the latest figure being at Rs -15.40 crore. Additionally, the debtors turnover ratio has also been decreasing each half year, indicating a slower pace in settling debts.

Furthermore, the company's net sales for the quarter have been the lowest in the last five quarters at Rs 20.26 crore, showing a negative trend in the near term. This figure has also fallen by -9.1% compared to the average net sales of the previous four quarters. Additionally, the cash and cash equivalents for the half year have been at its lowest in the last six periods, indicating a deterioration in short-term liquidity.

Overall, Sunil Healthcare's financial performance for the quarter ending September 2024 has been negative, with some areas showing improvement while others need attention. Investors should carefully consider these factors before making any decisions regarding the company's stock.